Health

STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 21:51:25 UTC.

Briefings

French pharma Servier announced that its $1.55 billion experimental drug sevasemten failed a pivotal Phase 3 trial for Becker muscular dystrophy, despite prior positive results in a smaller study. The trial was placebo-controlled and lasted approximately 18 months, with no statistically significant improvement observed in the primary endpoint. Servier is currently analyzing the data to understand the discrepancy between earlier findings and the current trial outcomes.

Key points

• Servier's drug sevasemten failed a Phase 3 trial for Becker muscular dystrophy, showing no significant improvement in the primary endpoint.
• The trial was a placebo-controlled study lasting 18 months conducted in France, with no approved treatments available for patients.

Context

Servier purchased the drug in June 2026 for $1.55 billion plus potential milestones. The drug was originally developed by Edgewise Therapeutics and had shown promise in a smaller randomized study before this pivotal trial.

Limitations

The evidence is limited to the French trial results and Servier's internal analysis. No additional background on patient outcomes or regulatory status is supplied. The study's long-term efficacy remains unverified.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 23:46:20 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidinku2b37hbpmqx7bjctjm7ni5u24f5plcdvbcp4izpyaqur2uru